Defining prognosis in the era of potent
antiretroviral therapy

Publications

Margaret May, Kholoud Porter, Jonathan A. C. Sterne, Patrick Royston, Matthias Egger, ART-CC (The Antiretroviral Therapy Cohort Collaboration) and CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe). Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. JCE (In Press).

May M, Royston P, Egger M, Justice AC, Sterne JAC, ART Cohort Collaboration. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Stat Med 2003; 23:2375-98

D'Arminio MA, Sabin CA, Phillips A, Sterne JAC, May M, Justice AC et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch.Intern Med 2005; 165:416-23

Chene G, Sterne JAC, May M, Costagliola D, Ledergerber B, Phillips AN et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362(9385):679-86

Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-29 (pdf of paper here)

Conference Presentations

9th International Workshop on HIV, Budapest, Hungary, April 2005

Robert Hogg, Jens Lundgren, Dominique Costagliola, Antonella D’Arminio Monforte, Bruno Ledergerber, Frank de Wolf, Peter Reiss, Gregory Fusco, Schlomo Staszewski, Geneviève Chêne, Andrew Philips, John Gill, Norbert Schmeisser, Margaret May, Jonathan A. C. Sterne, Matthias Egger, and ART Cohort Collaboration. Rates of viral suppression and regimen change according to initial HAART regimen. A collaborative analysis of 12 prospective cohort studies.

Jonathan A.C. Sterne, Margaret May, Stephen Cole. Can we estimate the optimum CD4 threshold for starting HAART in antiretroviral-naïve HIV-infected individuals?

12th Conference on Rtroviruses and Oportunistic Infections Boston, USA, Feb 2005

Robert Hogg, J Lundgren, D Costagliola, A Monforte, B Ledergerber, F De Wolf, G Fusco, S Staszewski, G Chêne, A Phillips, J Gill, J Rockstroh, M May, J Sterne, M Egger and ART-CC. Mortality rates according to initial HAART regimen: a collaborative analysis of 12 prospective cohort studies.

Francois Dabis, M Schechter, M Egger, and ART-LINC/ART-CC Study Groups. Response to Highly Active Antiretroviral Therapy in low- and high-income countries: Analysis of clinical databases from 4 continents.

AIDS 2004, Bangkok, July 2004

Margaret May and Jonathan Sterne for ART-CC. Changes in the effect of prognostic factors with time on HAART: ART Cohort Collaboration.

8th International Workshop on HIV, Montreux, Switzerland, March 2004

Margaret May for ART-CC. Changes in hazard of AIDS and/or death in patients on HAART over time.

Caroline Sabin on behalf of the ART Cohort Collaboration. Decline in incidence of clinical AIDS events following initiation of HAART: do some patients experience a greater benefit from HAART than others?

Matthias Egger for the ART Cohort Collaboration. Progression to AIDS or death up to 5 years after initiating HAART: Multicohort analysis of 19,086 treatment naïve patients.

7th International Workshop on HIV, Fiuggi, Italy, March 2003

Margaret May for ART-CC, Kholoud Porter for CASCADE, Patrick Royston. Validation of ART-CC prognostic model for progression to AIDS or death using independent data from the CASCADE collaboration.

François Dabis, Matthias Egger for the ART Cohort Collaboration. Closing the Outcome Gap? Proposal for a Cohort Collaboration on HAART in Resource-Poor Settings.

Matthias Egger for the ART Cohort Collaboration. Long-term prognosis of HIV-1 infected drug naïve patients starting potent antiretroviral therapy.

10th Conference on Retroviruses and Opportunistic Infections Boston, USA, Feb 2003

J. A. C. Sterne, M. May, D. Costagliola, P. Pezzotti, B. Ledergerber, F. de Wolf, J. Lundgren, J. S. Fusco, S. Staszewski, F. Raffi, R. S. Hogg, A. N. Phillips, M. J. Gill, G. Fatkenheuer, G. Chêne and ART-CC. Does it matter where you came from? Prognosis of patients starting potent therapy, according to initial response.

AIDS 2002, Barcelona, July 2002

M May, J A C Sterne, D Costagliola, P Pezzotti, B Ledergerber, F de Wolf , J D Lundgren, A C Justice, V Miller, G Chêne, F Dabis, R S Hogg, C Sabin, M J Gill, B Salzberger, M Egger. Construction and validation of a prognostic model for progression to AIDS or death in drug-naïve patients starting potent antiretroviral therapy. ART Cohort Collaboration.

G Chêne, M May, D Costagliola, A d'Arminio Monforte, C Junghans, F de Wolf, J D Lundgren, G Fusco, V Miller, C Leport, F Dabis, R S Hogg, A N Phillips, M J Gill, B Salzberger, J A C Sterne, M Egger. Prognosis of HIV-1 infected drug naïve patients starting potent antiretroviral therapy. ART Cohort Collaboration.

6th International Workshop on HIV, Sintra, Portugal, March 2002

Margaret May, Matthias Egger, Jonathan Sterne, on behalf of the ART Cohort Collaboration. Construction and validation of a prognostic model for progression to AIDS or death in 12,574 drug-naïve patients starting potent antiretroviral therapy.

Jonathan Sterne, Margaret May, Matthias Egger, on behalf of the ART Cohort Collaboration. Factors predicting progression to AIDS or death 6 months after starting potent therapy: Multicohort analysis of 12,574 patients.

Matthias Egger, Jonathan Sterne, Margaret May, on behalf of the ART Cohort Collaboration Opportunistic events in drug-naïve patients starting potent antiretroviral therapy: Reduction of incidence over time and importance of baseline prognostic factors.

Matthias Egger, Margaret May, Jonathan Sterne, on behalf of the ART Cohort Collaboration. Prognosis of drug-naïve patients starting potent antiretroviral therapy: Does the initial regimen matter?

5th International Workshop on HIV, Monte Carlo, April 2001

Margaret May, Mathias Egger on behalf of the ART cohort collaboration. Baseline characteristics and viral and immunological response to HAART: Preliminary results from the ART cohort collaboration.

Mathias Egger, Margaret May on behalf of the ART cohort collaboration. Progression to AIDS or death in drug-naïve patients starting HAART: Preliminary results from the ART cohort collaboration.

Jonathan Sterne, Matthias Egger on behalf of the ART Cohort Collaboration.

Assessing and Explaining Heterogeneity in Clinical, Virological and Immunological

Response to HAART: The ART Cohort Collaboration.